Europe Lymphedema Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Condition Type (Primary Lymphedema and Secondary Lymphedema), Treatment Type (Laser Therapy, Compression Devices and Bandaging, Drug Therapy, Physiological Proc

Europe Lymphedema Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Condition Type (Primary Lymphedema and Secondary Lymphedema), Treatment Type (Laser Therapy, Compression Devices and Bandaging, Drug Therapy, Physiological Procedures {Lymphovenous Anastomosis (LVA) and Vascularized Lymph Node Transfer (VLNT)}, Debulking Procedures {Surgical Debulking, Liposuction, and Others}, and Others), and End User (Hospitals, Clinics, Clinical Research Organizations, and Others) 

The lymphedema treatment market in Europe is expected to grow from US$ 2,801.39 million in 2021 to US$ 3,953.12 million by 2028; it is estimated to grow at a CAGR of 5.0% from 2021 to 2028. According to the Cleveland Clinic report, lymphedema can develop when there is damage to the lymphatic system or disruption in lymphatic damage. For example, lymph fluids drain into soft tissues, causing swelling and can occur anywhere in the body, with most cases occurring in arms and legs. Apart from that, cancer surgeries, radiation treatments, and other medical conditions raise the risk of lymphedema among patients. Additionally, the rise in gynecologic oncologic population, increase in body mass index, rise in insufficient levels of physical activity, and increase in the presence of pre-treatment lymphedema are witnessed as potentially high-risk factors of lymphedema development. For instance, oncological surgical procedures such as sentinel lymph nodes biopsy and radical dissection requiring excision of regional lymph nodes or vessels result in secondary lymphedema. According to one report, lymphedema can occur after any cancer or its treatment affecting lymph node drainage. For example, it has been reported that it can occur within days and up to 30 years after the treatment for breast cancer. Also, 80% of patients experience onset within three years of surgery, and the remainder develops edema at a rate of 1% per year. Additionally, a large patient pool suffers from lower-limb lymphedema, particularly women after treatment for gynecological cancer, with the highest prevalence (36%) among vulvar cancer survivors and lowest prevalence (5%) among ovarian cancer survivors. Further, the overall incidence of arm lymphedema ranges from 8% to 56% at two years post-surgery. Furthermore, lymphedema may and do occur in the trunk, in addition to limbs. For example, radiation therapy to the chest wall is associated with the development of edema, particularly in the irradiated breast. Additionally, the healthcare system requires highly advanced treatment products. Therefore, major players highly focus on new and innovative product launches and approvals. Furthermore, the surging volume of lymphedema prevalence fuels the demand for lymphedema treatment, ultimately contributing to overall market growth.

Based on condition type, the secondary lymphedema segment led the Europe lymphedema treatment market in 2020. Secondary lymphedema is an acquired disorder resulting from obstruction or damage to the lymphatic system. Also, secondary lymphedema may occur owing to trauma, tumors, or after radiation therapy for cancer or surgery for removing lymph nodes. Apart from this, the report states that secondary lymphedema is associated with adverse physical and psychological consequences among women with breast cancer (BC). Therefore, secondary lymphedema is arguably the most problematic and associated complication of breast cancer treatment. For instance, the incidence is generally accepted at approx 30% and reported vary greatly, ranging between 2% and 83%. Moreover, the Frontiers S.A. report states that secondary lymphedema is currently more common due to increasing cancer rates, affecting 1 in 1,000 persons where 24-49% of cancer patients develop secondary lymphedema after receiving cancer treatment.

Countries in the European regions were profoundly affected due to the COVID-19 pandemic. For instance, countries such as Italy, Spain, and France have reported the highest number of positive cases and have registered the maximum number of deaths. For instance, according to the Worldsometer, as of January 2022, 101,188,010 total cases and 1,565,203 deaths had been registered due to the COVID-19 pandemic in Europe. Further, countries across Europe witnessed a resurgence in COVID-19 cases after successfully mitigating outbreaks early in the year. Lockdowns were introduced in the UK, Spain, Italy, and Ireland, as per the European Centre for Disease Prevention and Control (ECDC). Due to the second wave of COVID-19 cases, many countries' governments are working towards boosting their treatments and regenerative medicines technologies to develop a treatment against various diseases, including COVID-19. Additionally, in the UK, the practice of cancer and neurological diseases changed. Increasing COVID-19 cases affected the diagnosis and treatment of diseases due to the diversification of the medical workforce and the decision to treat the critically ill. Due to the COVID-19 pandemic, many research organizations focused more on COVID-19 studies and are working hard to understand the virus better. The lymphedema treatment market witnessed a shortfall at the beginning of the COVID-19 crisis due to disruption in the supply chain and slumped demand for medical devices (used for the treatment of lymphedema) due to the lockdown announced by most European countries. Additionally, appointments and operations had been delayed in many clinics worldwide due to increasing cases, as approximately 40% of the diagnosed COVID-19 cases required hospitalization; and some critical cases were admitted to intensive care units (ICU). According to an article in Vascular News, in the first week of the pandemic outbreak, there was an 80% reduction in beds and an 84% reduction in operating rooms for elective procedures, with 43% of hospitals in Italy not doing any elective surgery. With the rising number of cases, there was a significant decrease in procedures due to a lack of healthcare resources. It also impacted the new product launches, sales, and growth of the market in the region. However, with the implementation of proper guidelines and protocols by the European Commission to reduce COVID-19 pandemic exposure and ease in restrictions on movement, the market is expected to grow in the forecast period.

The overall Europe lymphedema treatment market size has been derived using both primary and secondary sources. To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market. The process also serves the purpose of obtaining an overview and forecast of the Europe lymphedema treatment market with respect to all the market segments. Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data and gain more analytical insights into the topic. The participants typically involved in this process include industry experts such as VPs, business development managers, market intelligence managers, and national sales managers—along with external consultants such as valuation experts, research analysts, and key opinion leaders—specializing in the Europe lymphedema treatment market. 3M Company, BSN medical GmbH, Huntleigh Healthcare Limited, Lohmann & Rauscher GmbH & Co. KG, Mego Afek ltd, Sigvaris Group, and Smith & Nephew are a few key players operating in the market in this region.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe lymphedema treatment market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Europe lymphedema treatment market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the lymphedema treatment market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution